TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence rate of guidelines for IV-tPA and/or endovascular treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity, specificity, negative predictive value and positive predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants able to ingest 15 FMT capsules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of action potentials generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Endocan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary Endocan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in T2* times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-h postprandial blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device-oriented composite endpoint (DOCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net adverse clinical endpoint (NACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial Blood Gasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid burden range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Tenderness Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Life Simple 7 (LS7) composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotype-specific pneumococcal serum IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Over active bladder V8 questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood oxygenation level dependent (BOLD) fMRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale of low-back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Vitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Calcium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants with a decrease in HbA1c of at least 1%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants reaching the treatment target of a HbA1c decrease of at least 1%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of precancerous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in unprotected sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants discontinuing BZRA treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fear ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Strength Muscular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance Muscular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate according to reduction in BPI most acute pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of correlation between real time and single breath EtO2 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term adverse health consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Complete recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With >= Grade 3 TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time between surgery and discharge home
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Self-assessed vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transient TBS-induced changes in motor evoked potentials (MEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transient TBS-induced changes in language performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diaphragm thickness and fraction of thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carotid-femoral arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3 months progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: 6 months progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Average Dose of Inflectra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Number of Inflectra Infusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PTSD Checklist score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: exercise capacity - cardiopulmonary exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise capacity - 6-min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Febrile Neutropenia and/or Grade IV Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Mayo score activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of AZD6244 absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNFM endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Region Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of chemotherapy-induced cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardio Vascular Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TVM-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate by Choi criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Time to Closure of Final Skin Layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Newly developed hemorrhagic transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 30 day Post-op NOTES feasibility outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of magnetic resonance imaging sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of magnetic resonance imaging sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of magnetic resonance imaging sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of all-cause death and heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in MSQoL-54 Physical Health Composite Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in MSQoL-54 Mental Health Composite Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EPO concentration UI/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophoretic profile of EPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admission for acute kidney injury
Endpoint domain: Adverse events/effects
Primary endpoint: Need of late perineal reconstruction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total number of retrieved mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent agreement of scratching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Static Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Words and phrases production
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: LARC prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall Success at 24 Months Relative to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Serious Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Range of Motion (ROM) Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited local and systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in laboratory parameters from baseline to end of vaccination phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of ROP prediction using urinary NTproBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of HIFU in local recurrent prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: post-prandial glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients who changed eating habits
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Composite of safety and tolerability as assessed by vital sign measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of safety and tolerability as assessed by physical examination findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of safety and tolerability as assessed by clinical laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of safety and tolerability as assessed by Electrocardiogram (ECG) assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of incidence, severity and outcome of all Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of complicated diverticular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ETDRS BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Injection-site Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing a Systemic Adverse Event After ProQuad® Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of epidermoid carcinoma of the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Achieved a Sustained Virological Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration-Aspiration Scale-liquid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Swallowing outcomes
Primary endpoint: Penetration-Aspiration Scale-paste
Endpoint domain: Physiological/clinical
Endpoint subdomain: Swallowing outcomes
Primary endpoint: Monocular Uncorrected Distance Decimal Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Uncorrected Near Decimal VA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician-Administered Rating Scale for Mania (CARS-M)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participants Who Experienced Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in attentional psychometric measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of silent myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall cardiac event rate
Endpoint domain: Mortality/survival
Primary endpoint: The Shortened Disabilities of the Arm, Shoulder and Hand Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Participants in Complete or Partial Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Units of alcohol consumed per drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: App activity score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Spectral Slope (SPEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Fractal Dimension (FRAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diabetes Self-Care Activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Absolute incidence of postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erectile Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Flowmetry Maximum Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flowmetry Post Void Residual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LM response score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction Time for Trials With High Abstraction Relative to Low Abstraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction Time for Trials With High Set-size Relative to Low Set-size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Correct for Trials With High Abstraction Relative to Low Abstraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Correct for Trials With High Set-size Relative to Low Set-size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fiberoptic Endoscopic Dysphagia Severity Scale (FEDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of accuracy/agreement of vMap™
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory side effect frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of circulating cell free deoxyribonucleic acid (ccfDNA) mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of SARS-CoV-2 in nasopharyngeal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of R0 Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Marginal integrity of Class V restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in radiographic response to treatment for solid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in radiographic response to treatment for central nervous system (CNS) tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute difference in Cardiac Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary or Cumulative Irritation Potential of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of chemotherapy induced cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kinetics of left ventricular global longitudinal strain (LV-GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cut-off value of global longitudinal strain (GLS) to predict chemotherapy induced cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kinetics of right ventricular longitudinal strain (RV-GLS and RV-FWLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kinetics of left atrial longitudinal strain (LASr, LAScd, LASct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial infarct size according to MR delayed enhancement scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: main cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Experienced TEAEs Leading to Death
Endpoint domain: Mortality/survival
Primary endpoint: CERAD-NP total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to intervention administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Crossover rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Responders at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year death-censored kidney allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Severity of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capability to evaluate pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resting pressure and squeezing pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal sphincters integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balloon expulsion test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Improvement Response Rate
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in International Prostate Symptom Scale (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Resistance Index (RI) of umbilical arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Pulsatility Index (PI) of umbilical arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Resistance Index (RI) of fetal middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Pulsatility Index (PI) of fetal middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Significant Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantity of HIV-1 RNA in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genital HSV Shedding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Congenital Heart Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Function of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps Central Activation Ratio (CAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quadriceps Maximal Voluntary Isometric Contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Freedom from atrial fibrillation/flutter/tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline levels of histamine, CGRP and VIP in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of WATS biopsies compared to Forceps biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes